Rhenium

6K Additive and Metal Powder Works Announce Strategic Partnership to Bring Pure Copper, Copper Alloys, and Bronze AM Powder to the Market

Retrieved on: 
Thursday, November 9, 2023
Tungsten, Plasma, EV, Stainless steel, Rhenium, Niobium, Copper, Organization, Titanium, Nickel, AM, MOU, Partnership, Powder, Alloy, MPW, Powder metallurgy

FRANKFURT, Germany, Nov. 9, 2023 /PRNewswire/ -- 6K Additive, a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys and Metal Powder Works (MPW), the leader in solid state powder production, announced today at the Formnext conference the signing of an MOU and strategic partnership to produce pure copper, copper alloys, leading to strategically important powders such as copper/nickel, and bronze alloy powders for additive manufacturing. The high yield production achievable with both Metal Powder Works' DirectPowder™ Process and 6K Additive's UniMelt® microwave plasma ensures economic advantages, faster time to market, and sustainable production from both feedstock creation and the production of these materials.

Key Points: 
  • The high yield production achievable with both Metal Powder Works' DirectPowder™ Process and 6K Additive's UniMelt® microwave plasma ensures economic advantages, faster time to market, and sustainable production from both feedstock creation and the production of these materials.
  • "The market for copper is eager for a scalable solution that can not only deliver high-quality material, but one that can bring simplicity to the supply chain with a very sustainable process," said Frank Roberts, President of 6K Additive.
  • "The synergies between our two organizations ensure customers can source their material sustainably, reliably, and with the quality that meets their stringent specifications."
  • This alliance with 6K Additive opens up MPW's technology to provide more materials to the AM market."

6K Additive and Metal Powder Works Announce Strategic Partnership to Bring Pure Copper, Copper Alloys, and Bronze AM Powder to the Market

Retrieved on: 
Thursday, November 9, 2023
Tungsten, Plasma, EV, Stainless steel, Rhenium, Niobium, Copper, Organization, Titanium, Nickel, AM, MOU, Partnership, Powder, Alloy, MPW, Powder metallurgy

FRANKFURT, Germany, Nov. 9, 2023 /PRNewswire/ -- 6K Additive, a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys and Metal Powder Works (MPW), the leader in solid state powder production, announced today at the Formnext conference the signing of an MOU and strategic partnership to produce pure copper, copper alloys, leading to strategically important powders such as copper/nickel, and bronze alloy powders for additive manufacturing. The high yield production achievable with both Metal Powder Works' DirectPowder™ Process and 6K Additive's UniMelt® microwave plasma ensures economic advantages, faster time to market, and sustainable production from both feedstock creation and the production of these materials.

Key Points: 
  • The high yield production achievable with both Metal Powder Works' DirectPowder™ Process and 6K Additive's UniMelt® microwave plasma ensures economic advantages, faster time to market, and sustainable production from both feedstock creation and the production of these materials.
  • "The market for copper is eager for a scalable solution that can not only deliver high-quality material, but one that can bring simplicity to the supply chain with a very sustainable process," said Frank Roberts, President of 6K Additive.
  • "The synergies between our two organizations ensure customers can source their material sustainably, reliably, and with the quality that meets their stringent specifications."
  • This alliance with 6K Additive opens up MPW's technology to provide more materials to the AM market."

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

Retrieved on: 
Friday, November 3, 2023
FDA, LM, Plus Therapeutics, Food, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ODD, Breast cancer, Cancer, Society, Therapy, Patient, Cohort, PSTV, Pharmaceutical industry, Rhenium

“Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Key Points: 
  • “Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • “LM is a rapidly progressing and fatal complication of several cancers, including breast cancer, and incidence continues to rise.
  • ODD status, together with the previously granted Fast Track designation, underscores the significant and urgent need for new treatment options for LM.
  • In addition to ODD, the FDA previously granted rhenium (186Re) obisbemeda Fast Track designation for the treatment of LM.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

Retrieved on: 
Friday, November 3, 2023
FDA, LM, Plus Therapeutics, Food, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ODD, Breast cancer, Cancer, Society, Therapy, Patient, Cohort, PSTV, Pharmaceutical industry, Rhenium

“Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Key Points: 
  • “Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • “LM is a rapidly progressing and fatal complication of several cancers, including breast cancer, and incidence continues to rise.
  • ODD status, together with the previously granted Fast Track designation, underscores the significant and urgent need for new treatment options for LM.
  • In addition to ODD, the FDA previously granted rhenium (186Re) obisbemeda Fast Track designation for the treatment of LM.

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, October 31, 2023
BAM, Pakistan Society of Neuro-Oncology, FDA, Cohort, GBM, LM, Plus Therapeutics, CGMP, Rhenium, CSF, Lurie, SNO, Conference, Research, Cerebrospinal fluid, Decompression (diving), KOL, Webcast, Ependymoma, Hand, GMP, Safety, Society, Therapy, Cancer, Patient, Glioblastoma, Bangladesh Technical Education Board, Completeness, PSTV, Pharmaceutical industry, Vaccine, Internet service provider, Fine chemical, Medical imaging

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent and upcoming business highlights.
  • Present the latest safety and efficacy data from the Phase 1 ReSPECT-LM trial at the annual SNO meeting in Vancouver on November 15-19, 2023.
  • Participate in virtual KOL webinar following SNO meeting to discuss GBM data presented at the SNO meeting.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Latest study demonstrates high efficacy in curing invasive non-melanoma skin cancer

Retrieved on: 
Wednesday, October 25, 2023
Neoplasm, Patient, Cutaneous squamous-cell carcinoma, Incidence, NMSC, Georgetown University Medical Center, BCC, University Medical Center, Head, Face, Basal-cell carcinoma, CSCC, Cryotherapy, Carcinoma, Cancer, Radiation, Ear, Rhenium, Safety, Skin cancer, Hypopigmentation, Nose, Dentistry, Pharmaceutical industry, Veterinary medicine

MUNICH, Oct. 25, 2023 /PRNewswire/ -- Results from a recently completed study show topical rhenium-188 skin cancer therapy to be a highly effective option for treating non-melanoma skin cancer (NMSC) of up to 3 mm thickness.1

Key Points: 
  • Research lead, Professor Tietze from the University Medical Center, Rostock says, "The study found rhenium skin cancer therapy to be a highly effective treatment for NMSCs, in particular, the cosmetic outcomes on the head and face.
  • The study involved 22 patients with 40 histologically confirmed NMSCs (57.5% basal cell carcinomas (BCCs), 12.5% cutaneous squamous cell carcinomas (cSCCs), 30% Bowen's disease lesions).
  • This study shows the efficacy of rhenium skin cancer therapy demonstrating a 97.5% response rate with 37 of the 39 lesions showing complete response at 12 months," adds Professor Tietze.
  • All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments.

MiRus Announces FDA 510(k) Clearance for Molybdenum-Rhenium (MoRe®) Low Profile Anterior Cervical and Lateral Lumbar Plating Systems

Retrieved on: 
Wednesday, October 18, 2023
FDA, ACP, MD, Spine, Vertebra, Catherine Disher, Dysphagia, Patient, ACDF, Risk, Surgeon, Integration, Rhenium, Birth control

ATLANTA, Oct. 18, 2023 /PRNewswire/ -- MiRus® announced  that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe®  plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.

Key Points: 
  • ATLANTA, Oct. 18, 2023 /PRNewswire/ -- MiRus® announced  that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe®  plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.
  • MoRe®, a proprietary molybdenum rhenium superalloy for medical implants, provides an unprecedented combination of strength, ductility, durability, and biological safety.
  • The proprietary molybdenum-rhenium alloy used in the Integrated MoRe® lateral  plate allows for a dramatically smaller footprint of tapered 2mm thickness, without sacrificing performance.
  • The Integrated MoRe® Lateral  Plate was awarded the 2023  Spine Technology Award for its clinical relevance, clinical problem solving and  likelihood of improving patient outcomes.

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases

Retrieved on: 
Tuesday, October 10, 2023
Cerebrospinal fluid, Cohort, Cancer, Plus Therapeutics, LM, SNO, Rhenium, Radiation, Pakistan Society of Neuro-Oncology, PSTV, Disease, FDA, Data monitoring committee, DSMB, Therapy, Society, CSF, Fast Track, Patient, Learning, CNS, Toxic leukoencephalopathy, Vaccine, Pharmaceutical industry, Part

AUSTIN, Texas, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it has completed dosing in Cohort 4 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors. In addition, the Company has completed the transfer of proprietary materials, protocols, and equipment from Biocept under the terms of the recently announced expanded agreement for CNSide, a cerebrospinal fluid (CSF)-based tumor cell capture and enumeration assay being utilized in the ReSPECT-LM clinical trial.

Key Points: 
  • Completion of dosing in Cohort 4 was the fastest enrollment of all the Cohorts to date.
  • The Company plans to initiate dosing in Cohort 5 this quarter, pending Data Safety Monitoring Board (DSMB) approval.
  • The acquired materials and protocols from Biocept help ensure Plus’ access to the CNSide assay in the ongoing ReSPECT-LM Phase 1 clinical trial with rhenium (186Re) obisbemeda.
  • Patients interested in learning more about the ReSPECT-LM trial can visit ClinicalTrials.gov ( NCT05034497 ).

MiRus® Announces Launch of Molybdenum-Rhenium Low Profile ATLAS™ MoRe® Foot and Ankle Plating System

Retrieved on: 
Monday, September 18, 2023
Ankle, Surgeon, Serum, Foot, Spine, MBA, Rhenium, More, Titanium, Chromium, Patient, MD, Mercy, Extremities, Alloy, Cobalt, Elective surgery, Fatigue, Borosilicate glass

ATLANTA, Sept. 18, 2023 /PRNewswire/ -- MiRus announces limited market release in the U.S. of its ATLAS™ MoRe® Foot and Ankle Plating System, the thinnest  foot and ankle plate on the market for treatment of foot and ankle conditions.

Key Points: 
  • ATLANTA, Sept. 18, 2023 /PRNewswire/ -- MiRus announces limited market release in the U.S. of its ATLAS™ MoRe® Foot and Ankle Plating System, the thinnest  foot and ankle plate on the market for treatment of foot and ankle conditions.
  • The ATLAS™ MoRe® Foot and Ankle Plating System is a world class product in the marketplace that furthers our commitment to low profile, fatigue resistant biofriendly implants," remarked Andy Bishop, VP of  Sales- Extremities.
  • "The MiRus Atlas plating system brings us the lowest profile plates as well as the  highest contourability, thanks to the MoRe alloy (Molybdenum-Rhenium alloy).
  • Finally, we have plates for the foot and ankle that are stronger, thinner and more flexible for our cases!

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

Retrieved on: 
Monday, September 11, 2023
Plus Therapeutics, Poster session, Rhenium, Report, LM, PSTV, Poster, Therapy, Conference, Pharmaceutical industry, Cancer

The conference is taking place October 2-3, 2023, in Galveston, Tex.

Key Points: 
  • The conference is taking place October 2-3, 2023, in Galveston, Tex.
  • The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM).
  • In August 2023, Plus Therapeutics received an advance payment of grant funds of approximately $1.9 million, as planned, as part of its overall $17.6 million award contract , which CPRIT executed in September 2022.
  • The contract provides for funding from CPRIT over the three-year grant period starting on August 31, 2022, and follows the expected increase of development costs as the ReSPECT-LM clinical trial progresses to later stages.